ipragliflozin: Clinical Trials

5 trials of ipragliflozin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 45Completed 4, Terminated 1

Follow ipragliflozin: new trials by email Literature Review of ipragliflozin trials Research Report on ipragliflozin

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
metformin, ipragliflozin, glimepiride - Type 2 Diabetes Mellitus
Phase 4TerminatedAstellas Pharma Korea, Inc.332017-04-252024-11-08
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Ipragliflozin, Insulin - Type 2 Diabetes Mellitus
Phase 4CompletedAstellas Pharma Inc1032016-07-292024-11-12
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
Ipragliflozin, metformin with pioglitazone - Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Phase 4CompletedYonsei University442016-04-262017-06-23
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Ipragliflozin - Type 2 Diabetes Mellitus
Phase 4CompletedAstellas Pharma Inc1002014-10-082024-11-08
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
ipragliflozin, placebo - Type 2 Diabetes Mellitus
Phase 4CompletedAstellas Pharma Inc2622014-03-312024-11-08

Conditions studied

Diabetes Mellitus, Type 2 (4)  ·  Diabetes Mellitus (1)  ·  Insulin Resistance (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Astellas Pharma Inc (3)  ·  Astellas Pharma Korea, Inc. (1)  ·  Yonsei University (1)

Countries

Japan (3)  ·  South Korea (2)

Results publications

PMID 29926400, PMID 30800562, PMID 31552641, PMID 31606880